Human papillomavirus vaccines

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 1, 2002, Pages 15-22

  Stanley, Margaret A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cervical carcinoma; Cytotoxic T lymphocytes; DNA vaccines; Human papillomavirus vaccines; Neutralizing antibody; VLPs

Indexed keywords

CANCER VACCINE; CAPSID PROTEIN; CHIMERIC PROTEIN; ONCOPROTEIN; POLYNUCLEOTIDE; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE MODEL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; GENITAL TRACT INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROPHYLAXIS; PROTEIN STRUCTURE; RAT; TUMOR MODEL; UTERINE CERVIX CARCINOMA; VIRUS CAPSID; VIRUS PARTICLE; VIRUS RECOMBINANT; WART VIRUS;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOTHERAPY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; RODENTIA;

EID: 0036082786     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
2. Immune responses to human papillomaviruses
3. Genital papillomaviruses - Prospects for vaccination
4. Immunization with viruslike particles induces long term protection of rabbits against challenge with cottontail rabbit papillomavirus
5. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
6. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus
7. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
8. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype
9. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: Correlation with competitive radioimmunoassay titer
10. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers
11. Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro
12. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16
13. HPV vaccine moves into late stage trials
14. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
15. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
16. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies
17. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA
18. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection
19. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies
20. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33
21. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway
22. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles
23. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T-lymphocytes in vaginal draining lymph nodes
24. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
25. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response
26. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T-cells in humans after in vitro vaccination
27. Papillomavirus-like particles induce acute activation of dendritic cells
28. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T-cell responses in vitro
29. Immunization with non-structural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas
30. Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge
31. Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: Effects on papilloma formation and regression in the cottontail rabbit papillomavirus - Rabbit model
32. Protection of rabbits from viral challenge by gene gunbased intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes
33. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability
34. Enhancement of capsid gene expression: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes
35. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits
36. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia
37. Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia
38. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs
39. DNA vaccine against oncogenic hamster cells transformed by HPV16 E6IE7 oncogenes and the activated ras oncogene
40. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity
41. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T-cells but lacks transforming activity
42. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7
43. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen
44. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
45. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells
46. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen
47. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine
48. Boosting with recombinant vaccinia increases HPV-16 E7-specific T-cell precursor frequencies of HPV-16 E7-expressing DNA vaccines
49. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene
50. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens
51. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer
52. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site
53. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of in mice
54. Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge
55. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T-cell immunity that correlates with their established tumors immortalized by HPV-16
56. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity
57. Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: In vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide
58. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand
59. Therapeutic potential of protein and adjuvant vaccinations of tumour growth
60. Detection of T-helper responses, but not of human papillomavirus-specific cytotoxic T-lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
61. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
62. Papillomavirus research update: Highlights of the Barcelona HPV 2000 International papillomavirus conference
63. A recombinant vaccinia virus encoding human papillomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
64. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer
65. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer
66. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells
67. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities
68. Human papillomavirus-specific cytotoxic T-lymphocytes in patients with cervical intraepithelial neoplasia grade III
69. Differential T-helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitudinal study
70. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α
71. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
72. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy
73. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression
74. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6